← Back to Search

Antifungal

UHE-103 Cream for Fungal Nail Infection/Athlete's Foot

Phase 1
Waitlist Available
Research Sponsored by Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 16
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

This trial is testing a new cream (UHE 103) against an existing one (Naftin) in people with jock itch or athlete's foot. The creams aim to treat these fungal infections by killing or stopping the fungus. Naftin is known for its effectiveness in treating various superficial infections, providing both antifungal action and relief from inflammation.

Eligible Conditions
  • Fungal Nail Infection/Athlete's Foot
  • Jock Itch
  • Athlete's Foot

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AUC (0-12 hours)
Adverse Events (AEs)
Local Skin Reactions (LSRs)

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: UHE-103 CreamExperimental Treatment1 Intervention
Subjects will apply at least a total of 4 grams\* of the test article, covering both feet twice daily for 2 weeks
Group II: Naftin (naftifine hydrochloride) Cream, 2%Active Control1 Intervention
Subjects will apply at least a total of 5 grams\* of the test article, covering the interdigital areas of both feet and to the groin once daily for 2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UHE-103 Cream
2022
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Therapeutics, Inc.Lead Sponsor
30 Previous Clinical Trials
3,870 Total Patients Enrolled
Tony AndrasfayStudy DirectorTherapeutics Inc. (CRO)
6 Previous Clinical Trials
520 Total Patients Enrolled
~11 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top